Aliquoting comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
After reconstitution, solutions are usually divided into single-use aliquots to limit repeated handling. Each aliquot is stored at a temperature appropriate for the peptide, with -20 °C or -80 °C common for longer-term laboratory storage. Freeze-thaw cycles are minimized because they can cause aggregation, precipitation, or loss of activity. Temperature monitoring and documented storage conditions support reproducibility across experiments. When a peptide is removed from storage, it is typically allowed to equilibrate before opening to reduce condensation.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or inert plastic | Compatibility depends on peptide and solvent |
| Headspace gas | Nitrogen or argon | Used to limit oxygen exposure |
| Common reconstitution solvent | Water or buffered aqueous solution | Organic co-solvents may be needed for hydrophobic peptides |
| Freeze-thaw stability | Varies by peptide | Aliquoting reduces repeated cycles |
| Documentation | Lot, date, concentration, storage location | Supports traceability and reproducibility |
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Handling begins when a peptide container is opened. Hygroscopic solids can absorb atmospheric water rapidly, so bench work should be brief and containers resealed with fresh desiccant. Weighing or transferring should occur in a low-humidity environment where possible. Static electricity may cause fine powders to cling to surfaces, leading to inaccurate mass measurements. Tools such as antistatic devices or grounded workstations reduce that problem. Good laboratory practice also includes labeling date, lot, and storage condition after each opening.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Reconstitution is a critical handling step. The appropriate solvent—often sterile water, phosphate-buffered saline, or a water-acetonitrile mixture—is chosen based on peptide solubility. Adding solvent gently down the vial wall and swirling, rather than vortexing, reduces foaming and shear stress. The resulting solution should be clear; visible particles indicate incomplete dissolution or contamination. Concentration is recorded accurately because it affects subsequent use. If the peptide is not fully soluble, a small amount of organic solvent or a different buffer may be required, but this changes the final composition.
Flavins in general have fluorescent activity when unbound (proteins bound to flavin nucleic acid derivatives are called flavoproteins). This property can be utilized when examining protein binding, observing loss of fluorescent activity when put into the bound state. Oxidized flavins have high absorbances of about 450 nm, and fluoresce at about 515-520 nm.
Using the various properties of molecules, such as the energy required to break bonds and the dipole moments of molecules, he established a scale and an associated numerical value for most of the elements — the Pauling Electronegativity Scale — which is useful in predicting the nature of bonds between atoms in molecules. In 1936, Pauling was promoted to chairman of the division of chemistry and chemical engineering at Caltech, and to the position of director of the Gates and Crellin Laboratories of Chemistry. He would hold both positions until 1958. Pauling also spent a year in 1948 at the University of Oxford as George Eastman Visiting Professor and Fellow of Balliol.
=== 1963–1998: Bob Rosenberg === In 1963, Rosenberg's son Bob became CEO of the company at age 25, and Dunkin' Donuts opened its hundredth location that year. Dunkin' Donuts was a subsidiary of Universal Food Systems at the time, a conglomerate of 10 small food-service businesses, and Dunkin' Donuts locations varied greatly in their menu options, with some selling full breakfasts and others serving only doughnuts and coffee. In the following years, the other businesses in the Universal Food Systems portfolio were sold or closed, and the company was renamed to Dunkin' Donuts. The menu and shop format was standardized, and various new menu items were introduced. In the early 1980s, counter service and ceramic coffee cups were replaced by self-service counters and paper cups. The chain went public in 1968 and was acquired by Baskin-Robbins owner Allied Lyons in 1990. Dunkin' Donuts expanded in the 1990s by buying out two rival chains: Mister Donut (which was founded by Bill Rosenberg's former partner Harry Winokur) and Dawn Donuts.
In 1990, Gorbachev introduced and assumed the position of the President of the Soviet Union, concentrated power in his executive office, independent of the party, and subordinated the government, now renamed the Cabinet of Ministers of the USSR, to himself. Tensions grew between the Union-wide authorities under Gorbachev, reformists led in Russia by Boris Yeltsin and controlling the newly elected Supreme Soviet of the Russian SFSR, and communist hardliners. On 19–21 August 1991, a group of hardliners staged a coup attempt. The coup failed, and the State Council of the Soviet Union became the highest organ of state power 'in the period of transition'. Gorbachev resigned as General Secretary, only remaining President for the final months of the existence of the USSR.
==== Syrian Arab Republics ==== In 2013, Damascus University instituted a Master's program in Medical Physics, which has significantly contributed to the training of numerous medical physicists across various university and local hospitals, as well as several universities within the Syrian Arab Republic. This program has facilitated the dissemination of knowledge through the publication of several external research articles addressing the role of medical physicists in oncology. Furthermore, it has resulted in the production of multiple academic textbooks in the field of medical physics.
Sources: en.wikipedia.org
=== 2019 revision of the SI === The definition of the dalton was not affected by the 2019 revision of the SI, that is, 1 Da in the SI is still 1/12 of the mass of a carbon-12 atom, a quantity that must be determined experimentally in terms of SI units. However, the definition of a mole was changed to be the amount of substance consisting of exactly 6.02214076×1023 entities, and the definition of the kilogram was changed as well. As a consequence, the molar mass constant (Mu) remains close to but no longer exactly 1 g/mol, meaning that the mass in grams of one mole of any substance remains nearly but no longer exactly numerically equal to the average mass of an entity in daltons, although the relative standard uncertainty of 4.5×10−10 at the time of the redefinition is insignificant for all practical purposes. Letting ent denote one entity, the smallest amount of any substance (retaining its chemical properties), one mole is an aggregate of an Avogadro number of entities, i.e. 1 mol = N0 ent ≈ (g/Da) ent. This means that the appropriate atomic-scale unit for molar mass is dalton per entity (Da/ent), equal to the constant Mu, very nearly equal to 1 g/mol. For Da/ent to be exactly equal to g/mol, the dalton would need to be redefined exactly in terms of the (fixed-h) kilogram and the Avogadro number so that 1 Da = (1/N0) g, satisfying the relationships N0 = g/Da and 1 mol = N0 ent = (g/Da) ent, thus conforming to the original mole concept—that the Avogadro number is the gram-to-dalton mass unit ratio.
=== Schizophrenia === Risperidone is effective in treating psychogenic polydipsia and the acute exacerbations of schizophrenia. Studies evaluating the utility of risperidone by mouth for maintenance therapy have reached varying conclusions. A 2012 systematic review concluded that evidence is strong that risperidone is more effective than all first-generation antipsychotics other than haloperidol, but that evidence directly supporting its superiority to placebo for negative symptoms is equivocal. A 2011 review concluded that risperidone is more effective in relapse prevention than other first- and second-generation antipsychotics with the exception of olanzapine and clozapine. A 2016 Cochrane review suggests that risperidone reduces the overall symptoms of schizophrenia, but firm conclusions are difficult to make due to very low-quality evidence. Data and information are scarce, poorly reported, and probably biased in favour of risperidone, with about half of the included trials developed by drug companies. The article raises concerns regarding the serious side effects of risperidone, such as parkinsonism. A 2011 Cochrane review compared risperidone with other atypical antipsychotics such as olanzapine for schizophrenia, concluding it produced a somewhat higher risk of extrapyramidal side effects. Long-acting injectable formulations of antipsychotic drugs provide improved compliance with therapy and reduce relapse rates relative to oral formulations.
== Early life and education == Eke was born at the University of Nigeria Teaching Hospital in Enugu State, Nigeria. He attended Federal Government College, Wukari in Taraba State, before completing his medical degree (MBChB) at the University of Calabar. He earned a Master of Public Health (MPH) from the Harvard School of Public Health, concentrating in health policy and management. He completed residency training in Obstetrics and Gynecology in Nigeria at the Nnamdi Azikiwe University Teaching Hospital, and later at Michigan State University Obstetrics and Gynecology residency training program (now University of Michigan Health - Sparrow) in the United States. He went on to complete dual fellowships in maternal-fetal medicine and clinical pharmacology at Johns Hopkins University, where he earned a doctor of philosophy (PhD) in clinical investigation through the Graduate Training Program in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.
== Applications == Triethylamine is commonly employed in organic synthesis as a base. For example, it is commonly used as a base during the preparation of esters and amides from acyl chlorides. Such reactions lead to the production of hydrogen chloride which combines with triethylamine to form the salt triethylamine hydrochloride, commonly called triethylammonium chloride. (R, R' = alkyl, aryl):
Victor Grignard assumed the existence of unstable tetrahedral intermediate in 1901, while investigating the reaction of esters with organomagnesium reagents. The first evidence for tetrahedral intermediates in the substitution reactions of carboxylic derivatives was provided by Myron L. Bender in 1951. He labeled carboxylic acid derivatives with oxygen isotope O18 and reacted these derivatives with water to make labeled carboxylic acids. At the end of the reaction he found that the remaining starting material had a decreased proportion of labeled oxygen, which is consistent with the existence of the tetrahedral intermediate.
Sources: en.wikipedia.org
Dry peptides are generally kept in sealed, desiccated containers at low temperature, often -20 °C or colder. Protection from light, moisture, and oxygen helps slow degradation. The exact condition depends on the peptide sequence and supplier guidance.
Aliquoting divides a solution into smaller portions so that each portion is handled once. This reduces repeated freeze-thaw cycles and limits contamination risk. It also makes it easier to track usage and maintain consistent test conditions.
Refreezing is possible for some peptides but can promote aggregation or precipitation. The effect depends on the peptide, solvent, concentration, and freezing rate. Many laboratory protocols therefore recommend single-use aliquots instead of repeated refreezing.
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.